and Asp 186 are strictly conserved among both prokaryotic and eukaryotic galactokinases. In addition to providing molecular insight into the active site geometry of the enzyme, the model also provides a structural framework upon which to more fully understand the consequences of the those mutations known to give rise to Type II galactosemia.
In most organisms, the conversion of ␤-D-galactose to glucose-1-phosphate is accomplished by the action of four enzymes that constitute the Leloir pathway as indicated in Scheme 1 (1) (2) (3) (4) . Galactokinase (EC 2.7.1.6), the focus of this investigation, catalyzes the second step in the pathway, namely the MgATP-dependent phosphorylation of the C-1 hydroxyl group of ␣-D-galactose to yield galactose-1-phosphate (5, 6) . Thus far, ϳ20 mutations (including base substitutions, base deletions, and larger deletions) have been identified in human galactokinase, which result in the diseased state referred to as Type II galactosemia (MIM 230200). This disease, the main symptom of which is early onset cataracts, is less severe than either Type I or Type III galactosemia, which are caused by defects in the galactose-1-phosphate uridylyltransferase or UDP-galactose 4-epimerase genes, respectively (7) (8) (9) (10) .
The molecular mechanism of cataract formation is unclear but it is thought to be similar to that sometimes suffered by diabetics. High blood concentrations of galactose (or glucose in the case of diabetics) result in high concentrations of the sugar being transported into the lens cells of the eye. These cells have unusually high levels of the enzyme aldose reductase, which catalyzes the conversion of the sugar to its corresponding sugar alcohol galactitol (dulcitol) in the case of galactosemics and sorbitol in the case of diabetics (11, 12) . Although the sugar can be transported across the cell membrane, the sugar alcohol cannot (13) (14) (15) . Therefore, it accumulates and increases the osmotic potential drawing in water. It appears that this uptake of water leads to damage and ultimately to the formation of cataracts.
Within the last year, the crystal structures of two bacterial galactokinases were reported (16, 17) . The structure of the enzyme from Lactococcus lactis was solved in the presence of galactose and a phosphate ion whereas that from Pyrococcus furiosus was determined with galactose and MgADP bound in the active site (16, 17) . Many of the equivalent residues to the sites of disease-causing mutations in the human enzyme could be located in both models and speculations were made about the reason for structural or kinetic dysfunction (18) . However, not all the disease-causing mutations could be mapped unambiguously onto these bacterial enzyme structures.
Galactokinase is known to be a member of the GHMP superfamily of small molecule kinases, which includes homoserine kinase, mevalonate kinase, and phosphomevalonate kinase, among others (reviewed in Ref. 18 ). Indeed, this family of proteins was originally identified on the basis of amino acid sequence identity (19) . According to all presently available structural and biochemical data, members of this family can be subdivided into two groups depending upon their catalytic mechanisms. The crystal structure of rat mevalonate kinase in complex with ATP shows an aspartate residue (Asp 204 ) in the active site which is positioned to act as a catalytic base and a lysine residue (Lys 13 ) that is thought to influence the pK a of the substrate hydroxyl group (20) . In contrast, in Escherichia coli homoserine kinase, the equivalent residue to the aspartate is an asparagine (Asn  141 ) , and there appears to be no other suitable residue close enough to act as a catalytic base (21, 22) .
Furthermore, there is no adjacent positively charged residue. Consequently, it has been hypothesized that homoserine kinase achieves catalysis through transition state stabilization alone (22) . Which of the two subgroups galactokinase falls into is presently unclear. The crystal structures of the enzyme from both L. lactis and P. furiosus reveal an aspartate residue in an approximately equivalent position to that found in mevalonate kinase and an arginine occupying the same position as Lys 13 (16, 17) . However, enzymological studies on the Saccharomyces cerevisiae enzyme (which also has an equivalent aspartate residue) showed little variation in the turnover number and specificity constants with respect to pH and negligible effects on addition of increasing mol fractions of deuterium oxide in place of water (23) . Similarly, the human enzyme showed no solvent deuterium isotope effect (24) . Both experiments would have been expected to show some effect on these kinetic constants if an ionizable residue was involved in a reaction step reflected in the measured parameters (25) .
Here we report the three-dimensional structure of human galactokinase in complex with Mg-AMPPNP 1 and ␣-D-galactose, determined to a nominal resolution of 2.5 Å. This investigation has allowed for a more complete description of the active site geometry of galactokinase and has unambiguously revealed the locations of the mutations known to cause Type II galactosemia.
EXPERIMENTAL PROCEDURES
Expression of the Selenomethionine-labeled Protein-Cultures of E. coli HMS174(DE3) cells harboring the plasmid encoding the human GALK1 gene, as described in Ref. 24 , were grown overnight in M9 minimal medium at 37°C. Subsequently, 15 ml of the overnight culture were used to inoculate each of 12 ϫ 2-liter baffled flasks containing 500 ml of M9 minimal medium supplemented with 5 mg/liter thiamine. Cultures were grown at 37°C to an OD 600 of ϳ0.9 and then cooled for 10 min in an ice/water bath. They were then transferred to an incubator at 16°C, and each flask was supplemented with 50 mg each of lysine, threonine, and phenylalanine and 25 mg each of leucine, isoleucine, valine, and selenomethionine. Following 20 min of additional growth, the cultures were induced with 1 mM isopropyl-1-thio-␤-D-galactopyranoside and allowed to grow for an additional 18 h. Subsequently, the cells were harvested by centrifugation at 10,000 ϫ g for 10 min, and the cell paste frozen in liquid nitrogen for storage at Ϫ80°C. Note that the recombinant plasmid employed in this investigation results in a His 6 tag at the N terminus of the protein.
Protein Purification-All protein purification steps were conducted on ice or at 4°C. The cell paste was thawed in three volumes of lysis buffer containing 50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, and 100 mM galactose (pH 8). Cells were lysed with four cycles of sonication and cooling (45 s of sonication separated by 5 min of cooling). Cellular debris was removed by centrifugation at 20,000 ϫ g for 30 min. The clarified lysate was loaded onto a 10 ml Ni-NTA agarose column (Qiagen) pre-equilibrated in lysis buffer. After loading, the column was washed with 100 ml of lysis buffer, followed by 100 ml of wash buffer, which contained an additional 10 mM imidazole. The protein was recovered by a linear gradient elution with 20 -300 mM imidazole in the lysis buffer. Protein-containing fractions were pooled on the basis of purity as visualized by SDS-PAGE and dialyzed against 10 mM Hepes, 200 mM NaCl, and 100 mM D-galactose (pH 8). The dialyzed protein was concentrated to ϳ7 mg/ml based on a calculated extinction coefficient of 2.05 ml/(mg⅐cm) (DNAstar Inc., Madison, WI). Galactose-dependent ATPase activity was verified using the standard pyruvate kinase/lactate dehydrogenase-coupled assay.
Crystallization-Large single crystals were grown at room temperature via batch methods using 6 -8% polyethylene glycol 8000, 2% Me 2 SO, 10 mM Mg-AMPPNP, and 100 mM HEPPS (pH 8). These crystals achieved typical dimensions of 0.5 mm ϫ 0.1 mm ϫ 0.1 mm in 2-3 weeks and belonged to the space group P2 1 with unit cell dimensions of a ϭ 73.2, b ϭ 109.6, and c ϭ 115.8 and ␤ ϭ 95.9
o . The asymmetric unit contained four polypeptide chains.
High Resolution X-ray Data Collection-Prior to flash-cooling, the crystals were harvested from the batch experiments and equilibrated in a synthetic mother liquor composed of 15% polyethylene glycol 8000, 150 mM NaCl, 100 mM D-galactose, 10 mM Mg-AMPPNP, 2% Me 2 SO, and 100 mM HEPPS (pH 8). The crystals were then serially transferred to a cryoprotectant solution composed of 25% polyethylene glycol 8000, 250 mM NaCl, 100 mM D-galactose, 2% Me 2 SO, 15% ethylene glycol, and 100 mM HEPPS (pH 8).
X-ray data were collected on a CCD detector at the COMCAT 32-ID beamline (Advanced Photon Source, Argonne National Laboratory, Argonne, IL). All x-ray data were processed and scaled with HKL2000 (26) . Relevant x-ray data collection statistics are presented in Table I .
X-ray Structural Analyses-The structure of human galactokinase was solved via MAD phasing with crystals of the selenomethioninesubstituted protein. The software package SOLVE was utilized to determine the positions of the 32 selenium atoms in the asymmetric unit and to generate initial protein phases (figure-of-merit ϭ 0.5) (27) . Solvent flattening and molecular averaging of the four polypeptide chains in the asymmetric unit with RESOLVE (figure-of-merit ϭ 0.65) resulted in an interpretable electron density map calculated to 2.5-Å resolution (28) . The "averaged" map allowed for a complete tracing of the structure (392 amino acids) with the exception of several residues at the N terminus and a surface loop near His 229 to Ser
233
. Four copies of the model were placed back into the asymmetric unit and alternate cycles of manual model building and least-squares refinement with the software package TNT reduced the R-factor to 20.1% for all measured x-ray data from 20.0-to 2.5-Å resolution (29) . The crystals diffracted to ϳ2.1-Å resolution, but because of anisotropy in the diffraction pattern, the least-squares refinement was truncated at 2.5-Å resolution. Relevant refinement statistics are presented in Table II . A Ramachandran plot analysis indicates that 85.1, 14.6, and 0.3% of the residues are in the most favored, the additional allowed, and the generously allowed regions, respectively.
RESULTS AND DISCUSSION
Structure of Human Galactokinase-The crystals of human galactokinase employed in this investigation contained four polypeptide chains in the asymmetric unit. In that the electron density was best defined for the fourth molecule, the following discussion will refer specifically to it unless otherwise stated. Note, however, that the backbone ␣-carbon atoms for the individual polypeptide chains in the asymmetric unit superimpose upon one another with root mean-square deviations of between 0.31 and 0.42 Å.
As indicated in Fig. 1a , the structure of human galactokinase, with overall dimensions of ϳ44 Å ϫ 56 Å ϫ 63 Å, can be envisioned as two domains. The N-terminal region initiates with a long ␣-helix of 15 residues, which flanks one side of a six-stranded mixed ␤-sheet. A four helical bundle surrounds the other side of this ␤-sheet. The C-terminal domain is dominated by six ␣-helices and two layers of anti-parallel ␤-sheet, each containing four strands. The location of the three structural motifs characteristic of the GHMP superfamily are indicated in Fig. 1a . Motif I, having the sequence 38 Val-Asn-LeuIle-Gly-Glu-His 44 , abuts one side of the galactose moiety where the side chain of Glu 43 and the backbone peptidic nitrogen of His 44 participate in hydrogen bonding interactions with the C-6 hydroxyl group of the sugar. In human galactokinase, Motif II is formed by 136 Gly-Gly-Gly-Leu-Ser-Ser-Ser-Ala-Ser 144 and envelopes the phosphoryl moieties of the nucleotide. Finally, Motif III, as indicated in Fig. 1a , is formed by 343 Met-Thr-GlyGly-Gly-Phe-Gly-Gly 350 . The backbone peptidic nitrogen of Gly 346 lies within 3 Å of a ␥-phosphoryl oxygen of AMPPNP. There are three cis-prolines in human galactokinase at positions 85, 104, and 121.
Earlier reports suggested that the quaternary structures of the galactokinases from E. coli, L. lactis, P. furiosus, yeast, and human are monomeric, whereas that isolated from Vicia faba seeds is dimeric (16, 17, 24, 30 -32) . Analysis of the crystalline packing arrangement for the four molecules in the asymmetric unit reveals that, in this study, they associate as dimers through similar secondary structural elements. One such dimer, formed between molecules 3 and 4 (as listed in the deposited coordinate file) is displayed in Fig. 1b 207 to Pro 212 extends the four-stranded anti-parallel ␤-sheet in the C-domain of one subunit into an eightstranded anti-parallel ␤-sheet across the dimer interface. The residues involved in the formation of the subunit:subunit interface are not conserved among eukaryotic galactokinases. As indicated in Fig. 1b , there is a disulfide bridge formed by the side chains of Cys 391 (one from each subunit). This occurs in both dimers in the asymmetric unit and is most likely a function of the crystallization conditions. Whether the dimeric quaternary structure of human galactokinase observed in this investigation is merely a function of crystalline packing or represents the state of the enzyme in vivo is unknown.
Active Site of Human Galactokinase-Electron density corresponding to the bound ligands, ␣-D-galactose and Mg-AMP-PNP, is presented in Fig. 2a . Those amino acid residues lying within ϳ3.5 Å of the sugar or nucleotide are displayed in 
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␤-phosphoryl oxygen. Additionally, the backbone peptidic nitrogen of Ser 140 is positioned within 2.8 Å of a ␥-phosphoryl oxygen and the backbone peptidic nitrogen of Ser 141 lies within 2.9 Å a ␤-phosphoryl oxygen. The magnesium ion is wedged between ␣-, ␤-, and ␥-phosphoryl oxygens with metal:oxygen distances of 2.3, 2.6, and 2.3 Å, respectively. At a resolution of 2.5 Å, it is not possible to completely define the coordination geometry surrounding the metal ion.
A closeup stereo view of potential interactions between the protein and both the sugar and the ␥-phosphoryl group of AMPPNP is presented in Fig. 3 . The C-1 hydroxyl oxygen, which is phosphorylated during the reaction, sits between two of the ␥-phosphoryl oxygens of the nucleotide and lies within 3.3 Å of the ␥-phosphorus. The side chain nitrogen of Arg 37 , namely N 2 , is within 3.4 Å of the galactose C-1 hydroxyl group and 3.1 Å of the third ␥-phosphoryl oxygen. In the case of mevalonate kinase, for example, it has been postulated that a similarly positioned lysine residue serves both to lower the pK a of the C-5 hydroxyl group of mevalonate and to aid in stabilization of the presumed pentacoordinated ␥-phosphate transition state (20) . As indicated in Fig. 3 A recent investigation of sugar recognition by human galactokinase demonstrated that 2-deoxy-D-galactose also functions as a substrate for the enzyme but N-acetyl-D-galactosamine, L-arabinose, D-fucose, and D-glucose are not phosphorylated (34) . Assuming that for catalysis to occur, all of the abovementioned sugars must bind to the protein in a similar orientation as that observed for galactose, it is now possible to provide a structural explanation for these results. deoxygalactose) are missing the C-6 hydroxyl group. As shown in Fig. 3 , both the side chain of Glu 43 and the peptidic nitrogen of His 44 participate in hydrogen bonding interactions with O-6 of galactose. The loss of these two electrostatic interactions between the protein and either L-arabinose or D-fucose most likely results in the inability of the respective sugar to bind to the enzyme. This is further supported by biochemical data demonstrating that these sugars do not function as inhibitors of the galactokinase reaction thereby ruling out an explanation of non-productive binding (34) . Interestingly, in the recent study of the sugar specificity exhibited by human galactokinase, it was shown that replacing Glu 43 with an alanine residue resulted in little effect on the steady state kinetics of the enzyme with its natural substrate, ␣-D-galactose. Hence, while the abolition of the C-6 hydroxyl group in arabinose and fucose results in no catalytic activity, deleting the side chain carboxylate of Glu 43 causes little change in the steady state kinetics of the enzyme. This contradiction can now be rationalized on the basis of the structure presented here. Replacement of Glu 43 with an alanine results in the loss of only one of the two hydrogen bonding interactions that occur between the protein and the normal sugar substrate. The hydrogen bond formed between the C-6 hydroxyl group of galactose and the peptidic NH group of His 44 most likely remains intact and thus still serves to properly orient the sugar within the active site. Finally, D-glucose and D-galactose differ simply by the hydroxyl configuration about C-4. Due to this difference in configuration, however, the hydroxyl group in glucose is no longer in the correct position to participate in hydrogen bonding interactions with the side chains of Asp 46 and Tyr 236 . Again, D-glucose does not function as a competitive inhibitor (34) .
Implications for the Catalytic Mechanism of GalactokinaseThe catalytic mechanisms of both homoserine kinase and mevalonate kinase, both members of the GHMP superfamily, have been the subject of several recent investigations (20, 22, 35) . X-ray studies of ternary complexes of homoserine kinase with homoserine and non-hydrolyzable ATP analogs have revealed the lack of a catalytic base positioned near the ␦-hydroxyl group of homoserine that is ultimately phosphorylated (22) . The apparent absence of an active site base has led to the proposal that the catalytic mechanism of homoserine kinase proceeds through stabilization of the transition state. Specifically, the close positioning of the substrate and the ␥-phosphate of the nucleotide within the active site is thought to result in the direct transfer of the proton from the ␦-OH group of homoserine to the ␥-phosphorus of ATP and attack of the ␦-oxygen on the ␥-phosphorus. The side chain hydroxyl group of Thr 183 has been shown to interact with the ␤-phosphate of the nucleotide, and thus may help to stabilize the transition state.
In the case of mevalonate kinase, the catalytic mechanism is believed to proceed via acid/base chemistry. It has been proposed that the conserved aspartate (Asp 204 in the rat enzyme or Asp 155 in the Methanococcus jannaschii protein) serves to abstract the proton from the C-5 hydroxyl group of mevalonate for its subsequent attack on the ␥-phosphorus of ATP. Additionally, there is a conserved lysine residue, (Lys 13 in the rat enzyme or Lys 8 in the M. jannaschii protein), which is hypothesized to lower the pK a of the substrate C-5 hydroxyl group. It is important to note, however, that in the case of the M. jannaschii protein, the crystal structure reported is only that of the uncomplexed enzyme (35) . Likewise, with the rat enzyme, the reported structure is that only of the binary complex with bound ATP (20) .
With respect to galactokinase, initial kinetic analyses of the human enzyme have suggested that its catalytic mechanism may be more similar to that proposed for homoserine kinase (24) . As can be seen in Fig. 3 , however, the carboxylate group of Asp 186 lies in an appropriate position to serve as a catalytic base. Likewise, the guanidinium group of Arg 37 is positioned closely to the carboxylate of Asp 186 (ϳ3 Å), the C-1 hydroxyl group of galactose (3.4 Å), and the ␥-phosphoryl moiety of the nucleotide (3.1 Å). Indeed, the structural results presented here suggest that, perhaps, the reaction mechanism of galactokinase proceeds via a similar mechanism as that proposed for mevalonate kinase. It is, however, intriguing that members of the GHMP superfamily are thought to function by quite distinct catalytic mechanisms. One of the obvious questions in the case of galactokinase and also in mevalonate kinase is whether the conserved aspartate serves as the catalytic base or rather is simply involved in substrate binding. Perhaps all members of the GHMP superfamily proceed via a similar mechanism which is not completely characterized yet and that the conserved aspartates in mevalonate kinase, phosphomevalonate kinase, and galactokinase function only in substrate binding. From the presently available biochemical and x-ray crystallographic data, it is not possible to rule out this possibility.
Similarities to the Bacterial Galactokinases-Human galactokinase shares amino acid sequence identities of 38 and 34% with the P. furiosus and the L. lactis enzymes, respectively. Shown in Fig. 4, a and b are superpositions of the models for these two bacterial enzymes onto the human galactokinase structure. The galactokinases from human and P. furiosus correspond with a root mean-square deviation of 1.4 Å for 310 structurally equivalent ␣-carbon atoms. The major difference is the absence of the first ␣-helix in the P. furiosus protein such that the human and bacterial proteins begin to superimpose at Ala 31 and Thr 5 , respectively. Additionally, the P. furiosus enzyme lacks the last ␤-strand at the C terminus and as a result the mixed ␤-sheet in its N-terminal domain contains five rather than six strands. The human and L. lactis galactokinases are more similar such that 353 equivalent ␣-carbons superimpose with a root mean-square deviation of 1.3 Å. The human and L. lactis polypeptide chains begin to match at Glu 11 and Thr 9 , respectively and the human enzyme contains two somewhat longer loop regions formed by Ser 79 -Gln 86 and Leu 92 -Leu 99 . Implications for Type II Galactosemia-The lack of a functional galactokinase in humans results in Type II galactosemia (MIM 230200) (7-10). This relatively rare genetic disease (the incidence of homozygotes in Caucasians is estimated to be 1 in 1,000,000 (7)) causes an increased risk of early onset cataracts and, in more severe cases, results in kidney, liver and/or brain damage. A number of different mutations in the galactokinase gene (GALK1), as listed in Table III , have been shown to give rise to galactosemia including both deletions and point mutations (36 -44) . The locations of these mutations in human galactokinase are shown in Fig. 5 . There is an apparent correlation between the biochemical consequence of the point mutation and the severity of the symptoms: mutations which give rise to the most severe symptoms, and near-zero blood galactokinase levels tend to be insoluble upon expression in E. coli suggesting improper folding (24, 44) . Mutations that cause reduced blood galactokinase levels and less severe symptoms can be expressed in bacteria but have impaired kinetic parameters compared with the wild-type protein.
Those mutations that give rise to insoluble versions of the human protein on expression in E. coli include P28T, V32M, As in the other cases described above, there is not enough room to accommodate the substitution to a methionine residue without major alterations in the protein backbone and/or side chains. The mutation of Ala 384 to a proline is especially interesting. In the wild-type enzyme, Ala 384 is positioned in a loop connecting the last two ␤-strands of the structure as can be seen in Fig. 5 . This loop is quite critical for structural integrity in that it connects the Nand C-terminal domains together. Examination of the model in this region reveals no space constraints issues such as those for the other mutations described above. However, the phi, psi angles adopted by Ala 384 in the wild-type protein are Ϫ110 o and Ϫ174 o , respectively. These are incompatible for a proline in this position where its phi value is restricted to ϳϪ60 o due to its unique pyrrolidine ring side chain and, as such, the mutation of Ala 384 to a proline would disrupt this loop region to a significant extent.
As listed in Table III , six naturally occurring mutations in galactokinase have been studied with regard to their kinetic parameters: H44Y, R68C, A198V, R239Q, G346S, and G349S. One of these mutant proteins, A198V, is soluble on expression in E. coli and has kinetic parameters, which are essentially indistinguishable from the wild-type (24) . In contrast with the other mutations, where cataract formation is a near certainty within the first few years of life, this mutation merely results in a higher incidence of cataracts in later life (41) . Ala 198 resides in a ␤-strand and is ϳ17 Å from the active site. Its C ␤ projects into a quite hydrophobic pocket formed by the side chains of Leu 40 , Leu 53 , Val 211 , Leu 213 , and Leu 295 . Replacement of an alanine in this position with a valine could easily be tolerated with slight changes in the side chain orientations of Leu 40 , Leu 53 , and Leu 213 while still maintaining the overall hydrophobic character of this region. It is thus not unexpected that this particular mutant protein demonstrates normal wild-type kinetic parameters. Of the remaining five mutations, those located near the active site include H44Y, G346S, and G349S. Both Gly 346 and Gly 349 belong to Motif III of the GHMP superfamily and it would be expected that any change would produce altered kinetic parameters. Indeed, in the model of human galactokinase presented here, the backbone peptidic NH group of Gly 346 is perfectly positioned to form a hydrogen bond with a ␥-phosphoryl oxygen of the AMPPNP ligand. With regard to His 44 , this highly conserved residue forms part of the galactose binding site and the main chain carbonyl group is within hydrogen bonding distance of O-6 of the sugar (Fig. 3) . Replacement of this residue with the bulkier tyrosine is likely to disrupt the local structure and may well result in steric hindrance in the active site, consequences of which would be entirely consistent with the kinetic changes observed in this mutant protein.
The remaining mutations presented in Table III , for which kinetic parameters have been measured, are R68C and R239Q. In the case of the R68C mutation, there are small reductions in both the k cat and K m for galactose, and an increase in K m for MgATP. This arginine is located at the end of the second ␤-strand with its side chain solvent-accessible and is more than 22 Å from the active site. With the R239Q mutation, biochemical analyses indicate reduced activity and lower thermal stability. This residue is positioned at ϳ11 Å from the galactose moiety in an ␣-helix defined by Glu 235 to Ala 249 (Fig. 5) . It is in this region that there is an observed break in the polypeptide chain backbone (Ser 230 -Ser 233 ) thus suggesting conformational flexibility in this area.
In conclusion, the three-dimensional structure of the ternary complex of human galactokinase with bound ␣-D-galactose and AMPPNP described here provides an unambiguous molecular scaffold upon which to more fully address the effects of mutations known to give rise to Type II galactosemia. Additionally, the model yields further insight into the active site geometry of this enzyme and poses new questions as to whether the catalytic mechanism of galactokinase is more similar to that proposed for homoserine kinase or mevalonate kinase. Further biochemical and structural analyses will be required to understand the intricacies of this fascinating small molecule kinase. These studies are currently in progress.
